Biotech funding is back!
Cornerstone Search Group’s Post
More Relevant Posts
-
Our leaders, CEO Jin-Long Chen and COO Lucinda Quan, recently sat down with Ron Leuty of San Francisco Business Times to discuss our vision at TCG Labs-Soleil. At the core of TCG Labs-Soleil lies a unique ecosystem: a blend of a dedicated venture fund and an independent R&D hub. This synergy is crafted to foster a portfolio of single-asset companies, enabling swift, science-focused decision-making. We're driven by a passion to push the boundaries of what's possible in biotech, creating an environment where our team can thrive, innovate, and make significant impacts on health care. Read the full article below. #Biotech #Innovation #TCGLabsSoleil #ScienceForGood https://lnkd.in/gaP5ww-Q
How a VC and a biotech founder plan to create a new biotech model - San Francisco Business Times
bizjournals.com
To view or add a comment, sign in
-
CEO | Board Director | Cell and Gene Therapy |Rare Disease Patient Advocate |Global Network | Women's Leadership
I really like this VC perspective. Great article on how this particular VC group is thinking about the advanced therapies catgory. ....“There’s often a public perception that we’re in the prediction game,” said Morgan, a partner at Khosla Ventures who oversees the firm’s biotechnology investments. “We’re not trying to be. As an early-stage venture investor, we’re trying to imagine the possible future and bring resources, people and technology to bear, to shift reality.”.... Alexander A. Morgan, MD PhD #celltherapy #cellandgenetherapy #genetherapy #regenerativemedicine #venturecapital #investing #funding #biotech #biotechnology #advancedtherapies #lifesciences #healthcare #investments #earlystage #earlystagestartups #drugdevelopment #delivery #geneediting #drugdelivery
Khosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery
biopharmadive.com
To view or add a comment, sign in
-
Clinical planning, patient engagement & recruitment, commercial optimisation | Account Executive EMEAI Strategic Solutions
There are just a couple more days left before BIO EUROPE SPRING starts and Citeline Commercial just published a really insightful article on InVivo. Biotechs have faced challenges in the last couple years on many aspects: achieving clinical and regulatory milestones, appeasing investors whom are less willing to take risks on early-stage assets, and a buyer’s market in favor of pharma dealmakers. Public markets have been difficult to reach in the last 12 months as well, and for venture capitalists, raising new funds has been a struggle. On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023. Looking forward to have some great discussions in Barcelona and please make sure you that you won't miss the panel discussions with our Director Thought Leadership at Citeline, Daniel Chancellor #citeline #invivo #funding #biotech #pharma #lifescience #bioeurope #bioeuropespring
The Biopharma A List: Taking The Pulse Of Newco Creation
invivo.citeline.com
To view or add a comment, sign in
-
🔬 Unveiling the Biotech Frontier: Insights from Early-Stage Investing! 🔍 Embark on a journey through the dynamic world of biotech innovation with McKinsey's latest research. Gain valuable insights into the trends, challenges, and opportunities shaping the future of life sciences. 💊✨ 💡 Key Takeaways: - Exploring the landscape of early-stage investments in biotech. - Unraveling trends that define the future of healthcare innovation. - Understanding the strategies driving success in life science startups. 🚀 Join the Conversation ! How are early-stage investments shaping the biotech landscape in your view? Share your thoughts below! Read more about the fascinating intersection of science, technology, and investment: https://lnkd.in/eds-vuTK #BiotechInnovation #LifeSciences #Investing #Biotechnology #InnovationInsights #LifeScienceInvesting #HealthcareInnovation #BiotechTrends #InvestmentStrategies #ScienceAndTechnology #StartupEcosystem #BiotechStartups #McKinseyResearch #FutureOfHealthcare
What early-stage investing reveals about biotech innovation
mckinsey.com
To view or add a comment, sign in
-
With the current downturn in Venture Capital Biotech Drug Therapeutics, how can General Partners as well as Startup Founders secure Capital going forward and resurrect investor confidence? - Imagine Biotech.ai may have a solution... Willow Shah-Neville from Labiotech.eu wrote a fantastic and insightful piece alluding to the biotech "Gold Rush" over the last 2 years, and the current downtown being faced with a significant drop in financing (48.6%), BUT ends off on a hopeful note referencing the co-founder of LongeVC, with a common consensus among experts is that the use of AI within life sciences will be a game-changer, attracting investors once more! #biotech #biotechnology #venturecapital
Gold rush over: what happens to biotech now that venture capital is out of reach?
https://www.labiotech.eu
To view or add a comment, sign in
-
“Biotech is complex, and an entrepreneurial journey should not be a path to learn while moving forward,” said Schilansky. “Specialist life science VCs also have a better understanding of what can be a long process, particularly if the venture in question is pre-clinical. A generalist’s lack of knowledge can lead to basic mistakes like underfunding operational excellence, inaccurate benchmarking, skipping steps, not thinking about the exit strategy, the end product and market.” #venturecapitalist #innovation #biotechnology #investmentstrategy #vcfunding #lifesciences
Meet the 'biotech mafia': how specialized biotech VC firms are dominating industry funding once again
https://www.labiotech.eu
To view or add a comment, sign in
-
Activation Capital is seeking #startups to participate in their NEW Frontier BioHealth program. APPLY NOW! https://lnkd.in/dBiSQuNZ - ❗ Application Deadline: June 17, 2024 - 🏁 Program Kickoff: August 8, 2024 - 🎉 Program End: November 22, 2024 - 💻 Location: All virtual except for three in-person events. Travel costs will be covered! -💰 Investment: We do not invest and we do not take any equity. - 🔬 Startups transitioning #lifesciences innovations from research to commercialization, particularly those originating from academic or federal research labs, are highly encouraged to apply. - 🌟 Startups with a clear commercialization path, some initial funding (dilutive or non-dilutive), a full-time founder, licensing, optioning, or the ability to demonstrate control of their IP are highly encouraged to apply. More About the Program: -Website: https://lnkd.in/dBiSQuNZ -Apply Here: https://lnkd.in/dAFb_XpE -Meet with Jackie to learn more: https://lnkd.in/dF3-Ga3h #medicaldevice #pharma #biotech #diagnostic
Frontier BioHealth - Activation Capital
https://activation.capital
To view or add a comment, sign in
-
🔬🦠🧬 Purification Specialist for ÄKTA™ chromatography systems | Providing Technical Knowledge & Expertise in the Life Sciences | Optimizing Productivity & Efficiency from Lab-Bench to BioProcess Scale | Keynote Speaker
The #biotech industry is complex, and requires a deep understanding of scientific and regulatory aspects, which may not align with the expertise of generalist investors. While large funds (a16z, Sequoia, etc.) can still assemble dedicated #lifesciences teams, smaller generalist funds often cannot withstand the scientific due diligence #biotech investing requires. Generalist investors faced a much higher risk profile that they could not mitigate with in-house expertise, which often resulted in halted investments. A good VC firm should bring more to the table than just capital. This is where specialized biotech VC firms come into play, e.g. Sofinnova Investments and Medixci, as they have more expertise in the industry. Specialist life science VCs also have a better understanding of what can be a long process, particularly if the venture in question is pre-clinical. A generalist’s lack of knowledge can lead to basic mistakes like underfunding operational excellence, inaccurate benchmarking, skipping steps, not thinking about the exit strategy, the end product and market. Therefore, since generalist investors have begun to exit the biotech industry, specialized biotech VC firms are now simply continuing to do what they were doing before, bringing critical expertise in understanding the nuances of biotech ventures.
Meet the 'biotech mafia': how specialized biotech VC firms are dominating industry funding once again
https://www.labiotech.eu
To view or add a comment, sign in
-
📈 Between 2020 and 2022 there was an influx of generalist investors in the biotech industry. 💉 This was largely down to the COVID-19 pandemic, as investors saw huge potential in new technologies, such as mRNA vaccines. But, now, these generalist investors appear to have backed off, leaving room for specialized biotech VC firms to lead innovation in the industry once more. 🤔 So, why did generalist investors exit the biotech scene? Well, ultimately, biotech requires a deep understanding of the field, and the limited scientific knowledge of generalist investors had a major impact, as they faced a much higher risk profile that they could not mitigate with in-house expertise, often resulting in halted investments. 🚀 This has meant that specialized biotech VC firms are now dominating the biotech investment scene once more, continuing to do what they have always done, bringing critical expertise in understanding the nuances of biotech ventures. So, to find out more about how specialized VCs are dominating the biotech sector again, read our latest article! 👇 https://loom.ly/PMuqDGk #biotechinvestment #VCfirms #innovationleadership #specializedbiotech #industryinsights
Meet the 'biotech mafia': how specialized biotech VC firms are dominating industry funding once again
https://www.labiotech.eu
To view or add a comment, sign in
-
Founding Partner - 🧬emagineHealth, the Digital-First, AI-Powered Marketing Agency for Healthcare & Biopharma. emagineHealth.com
𝘽𝙞𝙤𝙥𝙝𝙖𝙧𝙢𝙖 𝙑𝘾 𝘼𝙘𝙩𝙞𝙫𝙞𝙩𝙮 𝙎𝙞𝙜𝙣𝙖𝙡𝙨 𝙖 𝙈𝙞𝙭𝙚𝙙 𝙊𝙪𝙩𝙡𝙤𝙤𝙠 Some good news for the biopharma sector. Latest analysis shows a significant uptick in VC funding in Q2. It seems like the industry is finally bouncing back from the slump of the past few years. The good news does come with a twist – not everyone is reaping the benefits. 🔍 Here’s a closer look: 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗦𝘂𝗿𝗴𝗲: Biopharma experienced a notable increase in VC funding this quarter, signaling renewed investor confidence. This is a positive shift from the pandemic's impact. 𝗦𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝗕𝗲𝗻𝗲𝗳𝗶𝗰𝗶𝗮𝗿𝗶𝗲𝘀: Despite the influx of cash, fewer companies are actually benefiting from this surge. Investors are becoming more cautious and selective, focusing on firms with mature clinical data and promising pipelines. It’s a case of quality over quantity. 𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝘆𝗻𝗮𝗺𝗶𝗰𝘀: The broader market remains challenging with fluctuating valuations and ongoing industry adjustments. This selective funding approach is a strategic move, ensuring investments go to companies that are more likely to succeed in the long run. 𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸: The future looks bright for certain niches within the sector. Areas like molecular glue degraders, epigenetic editing, and macrocyclic peptides are poised for growth in 2024 and beyond. Investors are keeping a close eye on these innovative fields. It’s fascinating to see how the sector is evolving. The pandemic forced a lot of companies to pivot and rethink their strategies. Now, we’re seeing a more mature and discerning investment landscape. This could lead to more sustainable growth and groundbreaking innovations in the long term. The selective approach by VCs means that only the strongest players with the most promising data are getting funded. This might seem tough for smaller or early-stage companies, but it’s a necessary evolution. It’s like a survival of the fittest scenario, which, in the end, will drive the industry forward with robust and viable solutions. #biotech #biopharma #funding #economy #financing #venturecapital
VC dollars pour into biopharma, with Q2 haul signaling sunshine ahead
fiercebiotech.com
To view or add a comment, sign in
29,732 followers